Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Trial of JX 594 Plus Best Supportive Care vs Best Supportive Care in Advanced Hepatocellular Carcinoma After Sorafenib Failure
KCT0000519Phase 2Recruiting
- Sponsor
- Jennerex Therapeutics
- Start
- Jul 2012
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing JX 594 plus best supportive care with Best supportive care alone (2 arms). Started Jul 2012; status: recruiting.
02
Drugs
recombinant vaccinia virus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0000519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000519.